Viewpoint Molecular Targeting(TM) Receives FDA Clearance of Investigational New Drug Application for Phase 1 Imaging Study for VMT-a-NET for Neuroendocrine Tumors
Viewpoint Molecular Targeting, Inc., a radiopharmaceutical company developing precision lead-212-based α-particle oncology therapeutics and complementary diagnostic imaging agents, announced that the U.S. Food and Drug Administration has cleared an Investigational New Drug application to commence a Phase 1 imaging study of VMT-
